Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 7, 2015-07 ,pp. : 1703-1710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 70, Iss. 1, 2018-01 ,pp. : 40-48

John Wiley & Sons Inc

Access to resources Recommend Favorite

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1627-1636

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 11, 2015-11 ,pp. : 2828-2836

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3255-3264

John Wiley & Sons Inc

Access to resources Recommend Favorite